A fter living donor liver transplantation (LDLT), tight control of immunosuppressive therapy is necessary to prevent acute rejections. The calcineurin (CN) inhibitor tacrolimus is one of the primary immunosuppressants used for the prevention of acute rejection after LDLT. In this context, therapeutic drug monitoring of tacrolimus is recommended to adjust the dosage because of its narrow therapeutic range and its highly interindividually variable pharmacokinetics. [1] [2] [3] In previous studies based on the twice-daily (TD) formulation of tacrolimus, the area under the curve (AUC) after the oral administration had a nearly linear relationship with the trough blood concentration (C 0 ). Therefore, the C 0 of tacrolimus is usually monitored to adjust the dosage of this drug. 4 The TD formulation was first developed with oral formulations of tacrolimus. Later, the once-daily (OD) prolonged-release formulation was developed to provide a more convenient formulation that was intended to improve patient adherence, and since then, several OD products have become available worldwide. Pharmacokinetic comparisons between the TD and OD formulations have been reported in a few studies mostly focused on the renal transplant field. 5, 6 The AUC and C 0 of tacrolimus in the OD formulation were shown to be nearly the same as in the TD formulation with no difference in the average dose of tacrolimus in the early stage after renal transplantation. 5 However, in a study using another extended-release OD product, the C 0 per daily dose ratio was higher in the OD formulation than in the TD formulation after renal transplantation. 6 Therefore, the pharmacokinetics of tacrolimus using the OD formulation may differ depending on the prolonged-release mechanisms.
In the liver transplant field, there have been several studies on the conversion of the tacrolimus formulation from TD to OD in the stable stage after transplantation. 7 However, studies using OD tacrolimus formulations in the early stage after LDLT are limited. In patients in the early stage after LDLT, the interindividual variability of tacrolimus pharmacokinetics can be more substantial than in LDLT patients in the stable stage or renal transplant patients. Liver function depends on the degree of regeneration and recovery of the grafted liver, and may affect tacrolimus metabolism. 8 Moreover, the absorption of tacrolimus may be low due to reduced movement of the small intestine in these patients. 9, 10 Therefore, information on tacrolimus pharmacokinetics using the OD formulation is needed in patients in the early stage after LDLT.
The measurement of CN phosphatase activity in peripheral blood mononuclear cells (PBMCs) is a pharmacodynamic biomarker used to evaluate the immunosuppressive effect of CN inhibitors. 11 The CN activity at the trough time point was suggested to be a surrogate indicator of overall CN activity throughout the dosing intervals after administration of the TD tacrolimus formulation in LDLT patients. 12 In this study, we investigated the pharmacokinetics and pharmacodynamics of tacrolimus using the OD formulation with simultaneous measurements of blood tacrolimus concentrations and CN activity in the early stage after LDLT and compared the data with previously reported data of the TD formulation. 12 
MATERIALS AND METHODS

Study Design
Nine patients, who had undergone primary LDLT at the Division of Hepato-Biliary-Pancreatic Surgery and Transplantation in Kyoto University Hospital between October 2010 and February 2012 and who were treated with the OD formulation (Graceptor; Astellas Pharma, Tokyo, Japan), were included in this study. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki as reflected in a priori approval by the Kyoto University Graduate School and Faculty of Medicine and Kyoto University Hospital Ethics Committee. Written informed consent was obtained from each patient.
Immunosuppressive therapy with tacrolimus was started in the morning on the day after the LDLT. The first oral daily dose of the OD formulation was 10 mg and was started at 9 o'clock in the morning. The initial daily dose in 2 patients was decreased by the decision of an attending surgeon. The dose was adjusted to target the blood tacrolimus concentration according to the trough measurement for 3 weeks after the transplantation. The target trough concentration was set between 10 and 15 ng/mL on postoperative days (PODs) 1-7, between 8 and 12 ng/mL on PODs 8-14, and between 6 and 10 ng/mL after POD 15. Patients treated with the OD tacrolimus formulation also received mycophenolate mofetil and methylprednisolone, according to a standard immunosuppressive regimen.
For comparison, we used previously reported data from 13 patients who had undergone LDLT between November 2007 and March 2009 and were treated with tacrolimus using the TD formulation (Prograf; Astellas Pharma, Tokyo, Japan) at 9 o'clock in the morning and evening. 12 The recommended first oral dose of tacrolimus in the TD formulation group was 0.05 mg/kg/d. After that, the dose of tacrolimus was adjusted to the target trough concentration as described for patients receiving the OD formulation. No patients received potent inhibitors of CYP3A4 during the study period.
Analytical Methods
Blood samples were taken every day before the morning administration of tacrolimus. Six additional samples were taken on a single day between PODs 19-23 (3 weeks after LDLT) at 1, 2, 4, 8, 12, and 24 hours after the tacrolimus administration. The tacrolimus concentration was measured using the Architect i1000SR (Abbott Japan, Tokyo, Japan). Samples were assayed as soon as possible after the blood collection. Otherwise, they were stored at 2208C until the assay could be performed.
CN phosphatase activity in PBMCs was measured using the remainder of the blood sample after the blood concentration measurement, as a pharmacological biomarker of tacrolimus. The assay of CN phosphatase activity in PBMCs was performed using a g-32 P-labeled regulatory subunit type II phosphopeptide as a substrate, according to a previously described procedure. 13 On the day of transplantation, a blood sample was obtained from some patients to determine the baseline CN activity before the administration of tacrolimus.
Pharmacokinetic and Pharmacodynamic Analyses
The AUC from 0 to 24 hours (AUC 0-24 ) after tacrolimus administration was calculated according to the trapezoidal rule in the OD formulation. For the comparison, AUC 0-24 in the TD formulation was calculated by twice the value of AUC 0-12 that was calculated according to the trapezoidal rule, because there was no tacrolimus concentration data obtained after 12 hours in the time course study in the TD formulation. 12 The highest observed concentration and associated time point were defined as the maximum drug concentration (C max ) and the time at which the maximum concentration occurred (T max ), respectively. The apparent clearance (CL/F) was calculated by dividing the corresponding daily dose on each study day by the AUC 0-24 . The area under the CN activity-time curve from 0 to 24 hours (AUA 0-24 ) after the tacrolimus administration was also calculated according to the trapezoidal rule in the OD group. The AUA 0-24 in the TD formulation was also calculated as twice the value of AUA 0-12 . The greatest observed CN inhibition, which caused a nadir of CN activity, and its associated time point were defined as CN nadir and T nadir , respectively. The relationship between the blood tacrolimus concentration and CN activity in PBMCs was analyzed using the following maximum inhibitory effect (E max ) model:
where CN is the CN activity at the blood concentration (C); E max is the maximum inhibitory effect attributable to the drug, which is assumed to be the same as the baseline activity; EC 50 is the blood concentration that gives a half-maximal effect.
The fixed parameters, E max and EC 50 , were estimated using the nonlinear mixed-effects modeling program NONMEM 7.2.0 (ICON Development Solutions, Ellicott City, MD). Interindividual variability for E max and EC 50 and residual variability were assumed to be a log-normal distribution and normal distribution, respectively. 13 
Statistical Analyses
Data are presented as the mean 6 the SD. Statistical analyses were performed using the statistical software package GraphPad Prism 5 (GraphPad Software, San Diego, CA). The statistical significance of the difference in mean values between the 2 groups was analyzed using an unpaired t test if the variances of the 2 groups were similar. Otherwise, the Mann-Whitney U test was used for the analysis. The variance between the 2 groups was analyzed using an F-test. The role of sex, ABO blood type, and primary disease was assessed using a x 2 test. Pearson correlation coefficient (r) was used to estimate the correlation between the tacrolimus blood concentration in the respective time point and AUC 0-24 after administration. A value of P , 0.05 was considered to be statistically significant.
RESULTS
Study Population
Pharmacokinetic and pharmacodynamic data from 9 LDLT patients treated with the OD tacrolimus formulation were compared with previously reported data from 13 patients treated with the TD formulation. 12 The patient's demographic characteristics are summarized in Table 1 . The mean age in the OD group was significantly younger than that in the TD group (51 versus 58 years, P = 0.048). The mean initial daily dose of tacrolimus in the OD group was approximately 5-times larger than that in the TD group (0.153 versus 0.032 mg/kg/d, respectively); however, the mean maintenance daily dose of tacrolimus 3 weeks after LDLT were not significantly different between the 2 groups.
Comparison of Daily Dose and Exposure
The mean daily dose of tacrolimus in the OD group gradually decreased in the early posttransplant period. After that, it tended to increase, and then reached a plateau; however, the mean daily dose of tacrolimus in the TD group was almost constant for 3 weeks after the transplantation (Fig.  1A) . The interindividual variability of the daily dose in the OD group was significantly larger than that in the TD group (P , 0.001). The doses and trough concentrations of tacrolimus on POD 1 were significantly higher in the OD group compared with those in the TD group (Figs. 1A, B) . Similar trough concentrations between the 2 formulations were obtained by day 4 after dose adjustments. Figure 2 shows the time course profiles of the tacrolimus blood concentrations and CN activities 3 weeks after LDLT. The tacrolimus blood concentrations at 4, 8, and 12 hours after administration in the OD group were significantly higher than those in the TD group, although the Data are presented as the number of patients or as the mean value 6 the SD. Data from the TD group were the same in the previous study. 12 *P-value was calculated using the x 2 test. †P-value was calculated using the unpaired t test. GRWR, graft-to-recipient weight ratio. C 0 was nearly equivalent (Fig. 2A) . The tacrolimus blood concentrations adjusted by the daily dose per body weight were not significantly different between the 2 groups (Fig. 2B) . The CN activities gradually decreased 4 hours after the administration and, after that, gradually increased as the tacrolimus blood concentrations decreased (Fig. 1C) . The CN activity returned to predose levels 12 hours after dose in the TD group or 24 hours after dose in the OD group. The CN activity at each time was not significantly different between the 2 groups. Table 2 shows the pharmacokinetic and pharmacodynamic parameters of tacrolimus in the OD and TD formulations. The median of T max in the OD group was significantly greater than that in the TD group. The C max , C max /C 0 , and AUC 0-24 were significantly greater in the OD group compared with those in the TD group. The CL/F and the examined pharmacodynamic parameters were not significantly different between the OD and TD groups.
Time Profiles of the Blood Tacrolimus Concentrations and CN Activities
Correlation Between Each Blood Concentration and the AUC of Tacrolimus
As mentioned in the previous report, 12 the C 0 was highly correlated with the AUC 0-12 after the administration of the TD formulation. However, the correlation between the AUC 0-24 and C 0 was not significant (r 2 = 0.189, P = 0.282) in the OD formulation (Fig. 3A) . Instead, the blood concentrations at 4, 8, 12, and 24 hours after dose (C 4 , C 8 , C 12 , and C 24 , respectively) showed a significant correlation with the AUC 0-24 as the r 2 value was . 0.5, and C 12 showed the highest correlation (r 2 = 0.995, P , 0.001).
Relationship Between the CN Activities and Blood Concentrations
The CN activities in PBMCs were inhibited in a concentration-dependent manner by tacrolimus in both the OD and TD formulations (Fig. 4A) . By applying the E max model to data obtained from 22 patients using the OD and TD formulations, the EC 50 was calculated as 21.8 ng/mL (95% *The P-value was calculated using the unpaired t test. †The P-value was calculated using the Mann-Whitney U test. ‡n = 8 patients. §n = 7 patients. ¶n = 12 patients. AUA 0-24 , area under the calcineurin activity-time curve from 0 to 24 hours; AUC 0-24 , area under the concentration-time curve from 0 to 24 hours; C 0 , predose blood concentration; CL/F, apparent clearance; C max , maximum blood concentration; CN 0 , predose calcineurin activity; CN nadir , calcineurin activity at maximum inhibition; T max , time corresponding to C max ; T nadir , time corresponding to CN nadir . confidence interval, 10.3-33.3) and the E max as 62.7 pmol/ min/mg protein (95% confidence interval, 53.7-71.7) using the nonlinear mixed-effects model. Interindividual variabilities for EC 50 and E max were 75.4% and 23.6% as a coefficient of variation %, respectively. Residual variability was 3.61 pmol/min/mg protein as an SD.
The CN activity at predose (CN 0 ) in the TD group showed a strong correlation with the AUA 0-24 (r 2 = 0.965, P , 0.001; Fig. 4B ). In the OD group, the CN 0 was also well correlated with the AUA 0-24 (r 2 = 0.775, P = 0.009). The slope of the 2 linear regressions was similar.
DISCUSSION
Unexpectedly, the C 0 was not correlated with the AUC 0-24 after administration of the tacrolimus OD formulation in the early stage after LDLT, showing that the C 0 monitoring may not be optimal for these patients. If clinicians target the same C 0 using the OD and TD formulations, the exposure of tacrolimus, namely the AUC 0-24 , can be substantially higher in the OD formulation than that in the TD formulation, and excessive immunosuppression may occur.
Although the C 0 and AUC 0-24 were not significantly correlated, the C 24 was well correlated with the AUC 0-24 in the OD formulation (Fig. 3) . The morning dose of tacrolimus was changed from the previous morning dose in some patients according to the tacrolimus concentration measurement. Although the C 24 reflects the AUC 0-24 of tacrolimus after the morning dose, the C 0 reflects the AUC 0-24 of tacrolimus after the morning dose on the previous day. Therefore, the C 24 , but not the C 0 , was well correlated with the AUC 0-24 . In fact, on the day of the time course study, 6 of 9 patients in the OD formulation took a different tacrolimus dose compared with the dose on the previous day. It was reported that the AUC 0-24 was well correlated with the C 0 both in the TD and OD tacrolimus formulations in the stable liver transplant recipients. 14 In addition, the C 0 has shown a good correlation with the AUC 0-24 in the TD and OD formulations in the early stage of renal transplantation. 15 Control of the tacrolimus trough concentrations and the daily dose adjustments of the OD formulation are considered to be manageable in the early stage of renal transplantation. In the early stage after LDLT, because the pharmacokinetics and the daily dose of tacrolimus are variable in the OD formulation, it is difficult to predict the AUC 0-24 of tacrolimus using the C 0 even 3 weeks after LDLT.
The daily maintenance dose of tacrolimus in the OD formulation was almost twice that in the TD group ( Fig. 1 and Table 1 ), although the C 0 was nearly equivalent (Fig. 1 and Table 2 ). These results were in agreement with the previous report, showing that when de novo liver transplant patients were administered tacrolimus as the OD or TD formulation, the dose of OD formulation became larger than that of TD formulation to get the same C 0 . 16 In addition, the AUC 0-24 tended to be higher in the OD formulation under the same C 0 (Fig. 2) , consistent with the previous report in the early stage of liver transplantation. 16 Because the CL/F in the TD and OD formulations were similar (Table 2) , we considered that the bioavailability of the 2 formulations was similar. A higher dose per time and day in the OD formulation made a higher peak concentration and higher AUC 0-24 in the OD group despite the same trough concentration. Similarly, a significant decrease in the tacrolimus C 0 was observed 1 month after a 1:1 conversion from the TD to OD formulation in longterm stable liver transplant recipients. 17, 18 Previous reports have demonstrated a safe conversion to OD formulation without increasing the risk of liver dysfunction or rejection. 19, 20 Taking these findings into consideration, the target trough concentration might be decreased in the OD formulation to prevent excess exposure at the treatment initiation or the conversion to the OD formulation in LDLT patients.
There were no differences in the relationship between the CN activity and tacrolimus concentrations depending on the tacrolimus formulations (Fig. 4A) ; so, we can expect the same degree of immunosuppression in the setting of the same target AUC of OD and TD formulations. However, because there is a large interindividual variability in the pharmacodynamics of tacrolimus, the AUC measurements alone are insufficient to predict the pharmacodynamic effects. Measuring the CN activity in addition to the concentrations of tacrolimus can be effective in deciding the individual pharmacotherapy. 11 In our previous report, 12 the correlation between the C 0 and the AUC 0-12 was shown in the TD formulation 3 weeks after LDLT, and the C 0 was suggested to be a good factor reflecting the AUC. In this study, we reanalyzed this using the same TD pharmacokinetic data: the relationship between the AUC 0-24 (y), calculated by doubling the AUC 0-12 , and C 0 (x) was shown to be y = 25.5*x + 23.4 in the TD formulation, whereas in the OD formulation, the relationship between the AUC 0-24 (y) and C 12 (x) was shown to be y = 25.3*x 2 14.3. The slope in the OD formulation was almost equal to the relationship mentioned above between the AUC 0-24 and C 0 in the TD formulation. This could mean that the C 12 is a useful marker reflecting the AUC 0-24 in the OD formulation, and monitoring the C 12 to target the similar range of C 0 in the TD formulation can prevent excessive exposure to tacrolimus in patients at an early stage of LDLT dosed OD. However, this suggestion should be validated by an additional study using a larger number of patients, and monitoring of C 12 might be quite impractical.
This study included some limitations. It should be noted that the concentrations of tacrolimus in whole blood were measured using the Abbott Architect assay in the OD formulation. In the TD formulation, the tacrolimus concentrations were measured using high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS), as previously reported. 21 Although the values obtained from the Abbott Architect and LC-MS/MS methods have been suggested to be well correlated, 22 immunoassays usually have a positive bias compared with LC-MS/MS method. 23 In addition, OD and TD studies were performed separately, encompassing very small numbers of patients (9 versus 13), with stable doses in the TD group and more variable doses in the OD group. Therefore, special attention should be paid to the interpretation of the present pharmacokinetic comparison between the OD and TD groups.
CONCLUSIONS
If clinicians target the same C 0 using the OD and TD formulations, systemic exposure to tacrolimus can be substantially higher after administration of the OD formulation than of the TD formulation, and excessive immunosuppression may occur in the early stage after de novo LDLT. Tacrolimus therapy using the OD formulation in the early stage of LDLT is associated with unstable pharmacokinetics even at 3 weeks after LDLT, which makes the usage of C 0 monitoring less reliable. Particular attention should be paid to the patients in the early stage after LDLT when they receive a tacrolimus OD oral formulation.
